Table 2

Clinical and laboratory effects of MARS therapy

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Parameter

Normal range

Before

After

Before

After

Before

After

Before

After

Before

After

Noradrenaline, μg kg^-1 min^-1

0.22

0.02

0.06

0.16

0

0

0.22

0.10

0.32

0.06

Creatinine

60–110 μM

307

142

132

239

171

234

241

144

164

107

Urea

2.9–7.1 mM

21

13

16

22

1

6

11

29

15

17

Ammonia

15–50 μM

67

47

HE grade

4

3

3

1

3

2

Bilirubin

<25 μM

161

210

654

528

260

182

484

137

510

326

Bile acids

0–6 μM

75

75

27

16

202

67

AA/β-OH-But

4.2

6.8

1.3

8

4

4.5

PDR ICG

>16% min^-1

4.4

5.5

4.3

5.2

4.3

5.4

5.6

5.2

Duration of treatment, h

24, 16

15, 13

5, 6

12, 16, 20

6, 6, 6

Outcome

ICU D/C, died in ward

Died in ICU

ICU D/C, died in ward

D/C home

Died in ICU

AA/β-OH-But, ratio of arterial acetoacetate to β-hydroxybutyrate (ketone body); D/C, discharged; HE, hepatic encephalopathy; ICU, intensive care unit; PDR ICG, plasma disappearance rate of indocyanine green (measured after an intravenous dose of 0.5 mg kg^-1 body weight with a non-invasive transcutaneous probe [Pulsion Medical System AG, Munich]).

Boyle et al. Critical Care 2004 8:280   doi:10.1186/cc2895